Intact Investment Management Inc. Takes $762,000 Position in Edwards Lifesciences Co. (NYSE:EW)

Intact Investment Management Inc. bought a new position in shares of Edwards Lifesciences Co. (NYSE:EW) in the fourth quarter, HoldingsChannel reports. The fund bought 10,000 shares of the medical research company’s stock, valued at approximately $762,000.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in Edwards Lifesciences by 0.6% in the third quarter. Vanguard Group Inc. now owns 51,633,416 shares of the medical research company’s stock valued at $3,577,163,000 after acquiring an additional 325,808 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Edwards Lifesciences by 9.2% in the 3rd quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company’s stock valued at $1,138,575,000 after purchasing an additional 1,390,427 shares during the last quarter. Brown Advisory Inc. grew its stake in Edwards Lifesciences by 5.7% during the 3rd quarter. Brown Advisory Inc. now owns 15,133,146 shares of the medical research company’s stock worth $1,048,424,000 after buying an additional 818,849 shares during the last quarter. Northern Trust Corp increased its position in Edwards Lifesciences by 3.9% during the third quarter. Northern Trust Corp now owns 6,357,473 shares of the medical research company’s stock worth $440,446,000 after buying an additional 241,347 shares during the period. Finally, WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST increased its position in Edwards Lifesciences by 16.8% during the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,100,000 shares of the medical research company’s stock worth $312,625,000 after buying an additional 590,000 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on EW. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. OTR Global raised shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, March 20th. Evercore ISI lowered their price target on Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a report on Friday. Finally, Royal Bank of Canada lifted their price objective on Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a report on Monday, April 15th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $92.71.

Edwards Lifesciences Trading Down 1.8 %

NYSE EW opened at $86.43 on Monday. The firm has a market capitalization of $52.02 billion, a price-to-earnings ratio of 37.25, a PEG ratio of 4.28 and a beta of 1.05. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12. The company’s 50 day moving average price is $90.28 and its 200 day moving average price is $78.95.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The business had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. On average, sell-side analysts predict that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the sale, the chief financial officer now owns 19,248 shares in the company, valued at $1,506,925.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 14,400 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the completion of the sale, the vice president now owns 173,849 shares in the company, valued at approximately $16,049,739.68. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total value of $567,993.95. Following the sale, the chief financial officer now owns 19,248 shares in the company, valued at $1,506,925.92. The disclosure for this sale can be found here. Insiders have sold a total of 194,004 shares of company stock worth $17,166,254 over the last quarter. 1.27% of the stock is owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.